TD Cowen Boosts Quanterix (NASDAQ:QTRX) Price Target to $16.00

Quanterix (NASDAQ:QTRX) had its price objective hoisted by TD Cowen from $13.50 to $16.00 in a research report released on Wednesday morning,Benzinga reports. TD Cowen currently has a hold rating on the stock.

Separately, Scotiabank lowered their target price on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating on the stock in a research report on Monday, August 12th.

Quanterix Price Performance

Quanterix stock opened at $11.44 on Wednesday. Quanterix has a 52-week low of $10.50 and a 52-week high of $29.70. The firm has a 50-day moving average price of $12.95 and a two-hundred day moving average price of $13.96.

Insider Activity

In other news, Director David R. Walt acquired 47,000 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was acquired at an average price of $13.29 per share, for a total transaction of $624,630.00. Following the completion of the acquisition, the director now directly owns 1,487,342 shares in the company, valued at $19,766,775.18. This represents a 3.26 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Quanterix

Hedge funds and other institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC raised its holdings in shares of Quanterix by 22.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 12,844 shares of the company’s stock worth $303,000 after purchasing an additional 2,340 shares in the last quarter. State Board of Administration of Florida Retirement System increased its holdings in shares of Quanterix by 42.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 14,341 shares of the company’s stock valued at $338,000 after buying an additional 4,250 shares in the last quarter. Lord Abbett & CO. LLC lifted its position in shares of Quanterix by 22.9% during the 1st quarter. Lord Abbett & CO. LLC now owns 1,757,153 shares of the company’s stock valued at $41,398,000 after acquiring an additional 326,876 shares during the last quarter. Picton Mahoney Asset Management boosted its stake in shares of Quanterix by 1,598.1% during the 1st quarter. Picton Mahoney Asset Management now owns 86,092 shares of the company’s stock worth $2,027,000 after acquiring an additional 81,022 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Quanterix by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 2,069,423 shares of the company’s stock worth $48,756,000 after acquiring an additional 14,390 shares during the last quarter. 86.48% of the stock is currently owned by institutional investors.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.